Black Diamond Therapeutics, Inc. (BDTX) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Black Diamond Therapeutics reported revenue of $70.0M. Net income was $22.4M (a 32.0% net margin), or $0.39 per diluted share. Operating margin was 17.9%. Operating activities generated $29.6M of cash. At fiscal year end, Black Diamond Therapeutics held $143.0M in total assets against $30.8M in total liabilities, including $21.0M of cash and equivalents.
Open the full interactive Black Diamond Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Black Diamond Therapeutics Key Stats
| Share Price | $1.68 |
|---|---|
| Market Cap | $96.4M |
| P/E Ratio | 4.3 |
| 52-Week Range | $1.61 – $4.87 |
| Shares Outstanding | 57.4 million (basic, 2026 Q2) |
Black Diamond Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $70.0M |
| Operating Income | -$69.6M | -$126.9M | -$92.8M | -$86.5M | -$78.8M | $12.5M |
| Pre-Tax Income | -$67.3M | -$125.6M | -$91.2M | -$82.4M | -$69.7M | $22.4M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$67.3M | -$125.6M | -$91.2M | -$82.4M | -$69.7M | $22.4M |
| Diluted EPS | -$2.05 | -$3.47 | -$2.52 | -$1.88 | -$1.27 | $0.39 |
Black Diamond Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$8.5M | -$15.1M | -$9.0M | -$9.9M |
| Diluted EPS | -$0.15 | -$0.26 | -$0.16 | -$0.17 |
Black Diamond Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $34.6M | $65.8M | $34.3M | $56.2M | $36.4M | $21.0M |
| Current Assets | $319.6M | $215.7M | $127.7M | $134.0M | $101.2M | $132.4M |
| Total Assets | $329.7M | $247.7M | $156.3M | $158.6M | $122.6M | $143.0M |
| Current Liabilities | $14.2M | $23.6M | $15.3M | $19.6M | $20.6M | $15.7M |
| Total Liabilities | $21.9M | $51.8M | $40.6M | $41.8M | $39.4M | $30.8M |
| Shareholders' Equity | $307.8M | $195.9M | $115.7M | $116.7M | $83.3M | $112.2M |
Black Diamond Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$52.1M | -$100.1M | -$85.1M | -$66.7M | -$62.3M | $29.6M |
| Cash From Investing | -$281.7M | $130.6M | $53.4M | $16.3M | $17.0M | -$44.9M |
| Cash From Financing | $214.9M | $729,000 | $177,000 | $71.9M | $25.5M | -$146,000 |
| Free Cash Flow | -$52.3M | -$102.9M | -$85.3M | -$66.8M | -$62.3M | — |
Figures from Black Diamond Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Black Diamond Therapeutics financials page for every line item.
Black Diamond Therapeutics Company Profile
| Ticker | BDTX |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Cambridge, Massachusetts |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001701541 |
Frequently Asked Questions
What was Black Diamond Therapeutics' revenue in fiscal 2025?
Black Diamond Therapeutics (BDTX) reported revenue of $70.0M for fiscal 2025.
What is Black Diamond Therapeutics' annual revenue history?
Black Diamond Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $70.0M.
What was Black Diamond Therapeutics' net income in fiscal 2025?
Black Diamond Therapeutics reported net income of $22.4M for fiscal 2025.
What was Black Diamond Therapeutics' earnings per share (EPS) in fiscal 2025?
Black Diamond Therapeutics' diluted EPS was $0.39 for fiscal 2025 (adjusted for any later stock splits).
What was Black Diamond Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Black Diamond Therapeutics reported revenue of $0.
How many shares of Black Diamond Therapeutics are outstanding?
Black Diamond Therapeutics reported a weighted average of 57.4 million basic shares outstanding in 2026 Q2.
What is Black Diamond Therapeutics' market cap?
Based on its latest closing price, Black Diamond Therapeutics (BDTX) has a market capitalization of about $96.4M.
When does Black Diamond Therapeutics' fiscal year end?
Black Diamond Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Black Diamond Therapeutics headquartered?
Black Diamond Therapeutics lists its business address in Cambridge, Massachusetts in its SEC filings.
Black Diamond Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →